Benchmarking internacional sobre a gestão estratégica da regulação em saúde
International Benchmarking on Strategic Management of Health Regulation
Análisis comparativo internacional sobre la gestión estratégica de la regulación en salud
Abstract (en)
The article explores best practices in strategic management across eight health regulatory agencies from various regions — Europe, North America, South America, and Oceania — are explored, with a focus on these institutions’ priorities for protecting and promoting health. Among the common strategic themes identified in the research are innovation, with the use of emerging technologies to improve evaluations and accelerate access to new therapies; environmental sustainability, through the promotion of ecological practices and responsible resource use; international collaboration to confront global threats such as pandemics and antimicrobial resistance; and clear, accessible communication, which is essential for consumers to make informed decisions. Furthermore, it was found that, in a transversal manner, the analyzed institutions are enhancing their risk management systems to anticipate, identify, and mitigate threats — an aspect particularly relevant in the face of health crises and rapid technological evolution. The study delves deeply into the practices of the European Medicines Agency and the Danish Medicines Agency, emphasizing management methodologies, governance structures, and monitoring processes that contribute to effective strategic management. It was also observed that recognition and incentive practices strengthen engagement and ensure sustainable results, offering a comprehensive and relevant perspective for improving health regulation globally.
Abstract (pt_BR)
Neste artigo, exploram-se as melhores práticas de gestão estratégica em oito agências reguladoras de saúde de diversas regiões — Europa, América do Norte, América do Sul e Oceania — com foco nas prioridades dessas instituições para proteger e promover a saúde. Entre os temas estratégicos comuns identificados na pesquisa, destacam-se a inovação, com o uso de tecnologias emergentes para melhorar avaliações e acelerar o acesso a novas terapias; a sustentabilidade ambiental, por meio do incentivo a práticas ecológicas e ao uso responsável de recursos; a colaboração internacional para enfrentar ameaças globais, como pandemias e resistência antimicrobiana; e a comunicação clara e acessível, essencial para que os consumidores tomem decisões informadas. Além disso, identificou-se que, de forma transversal, as instituições analisadas estão aprimorando seus sistemas de gestão de riscos para antecipar, identificar e mitigar ameaças — aspecto especialmente relevante diante de crises sanitárias e da rápida evolução tecnológica. No estudo, analisam-se em profundidade as práticas da Agência Europeia de Medicamentos e da Agência Dinamarquesa de Medicamentos, com ênfase em metodologias de gestão, estruturas de governança e processos de monitoramento que contribuem para uma gestão estratégica eficaz. Observou-se, ainda, que práticas de reconhecimento e incentivo fortalecem o engajamento e garantem resultados sustentáveis, o que oferece uma visão abrangente e relevante para aprimorar a regulação em saúde globalmente.
Abstract (es)
El artículo explora las mejores prácticas de gestión estratégica en ocho Agencias Reguladoras de salud de diversas regiones —Europa, América del Norte, América del Sur y Oceanía— con un enfoque en las prioridades de estas instituciones para proteger y promover la salud. Entre los temas estratégicos comunes identificados en la investigación se destacan la innovación, mediante el uso de tecnologías emergentes para mejorar las evaluaciones y acelerar el acceso a nuevas terapias; la sostenibilidad ambiental, a través del fomento de prácticas ecológicas y el uso responsable de los recursos; la colaboración internacional para enfrentar amenazas globales, como pandemias y resistencia antimicrobiana; y la comunicación clara y accesible, esencial para que los consumidores tomen decisiones informadas. Además, se identificó que, de forma transversal, las instituciones analizadas están mejorando sus sistemas de gestión de riesgos para anticipar, identificar y mitigar amenazas —aspecto especialmente relevante frente a crisis sanitarias y la rápida evolución tecnológica—. En el estudio, se analizan en profundidad las prácticas de la Agencia Europea de Medicamentos y de la Agencia Danesa de Medicamentos, con énfasis en las metodologías de gestión, estructuras de gobernanza y procesos de monitoreo que contribuyen a una gestión estratégica eficaz. También se observó que las prácticas de reconocimiento e incentivos fortalecen el compromiso y garantizan resultados sostenibles, lo que ofrece una visión amplia y relevante para mejorar la regulación en salud a nivel global.
References
Abbott, K. W., & Snidal, D. (2010). International regulation without international government: Improving IO performance through orchestration. The Review of International Organizations, 5, 315-344. https://doi.org/10.1007/s11558-010-9092-3
Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. (2024). Planificación Estratégica ANMAT 2024-2027. ANMAT. https://www.argentina.gob.ar/sites/default/files/1000-pea24-27_-_planificacion_estrategica_anmat_2024-2027.pdf
Agência Nacional de Vigilância Sanitária. (2024). Plano Estratégico 2024-2027: Inovação e Eficiência na Regulação Sanitária. Anvisa. https://www.gov.br/anvisa/pt-br/acessoainformacao/acoeseprogramas/planejamento-estrategico/2024-2027/pe_2024_2027_atualizacao_10_6_2024.pdf
Bizimana, R. (2024). The Impact of Public Health on Health Regulation. Research Invention Journal of Scientific and Experimental Sciences. https://doi.org/10.59298/RIJSES/2024/4225
Bryson, J. M. (2018). Strategic planning for public and nonprofit organizations: A guide to strengthening and sustaining organizational achievement. John Wiley & Sons.
Committee of Sponsoring Organizations of the Treadway Commission. (2017). Enterprise Risk Management: Integrating with Strategy and Performance. COSO.
da Silva, D. A., & da Silva, R. M. (2024). The police power of the National Health Surveillance Agency — Anvisa. Archives of Cancer Science and Therapy, 8(1), 63-76. https://dx.doi.org/10.29328/journal.acst.1001046
Danish Medicines Agency. (2022). Mission, Vision and Strategy 2022-2026. Danish Medicines Agency. https://laegemiddelstyrelsen.dk/en/about/mission,-vision-and-strategy/#idDDD0DB70DC424AD7965604513D519064
European Medicines Agency. (2020). European Union Medicines Agencies Network Strategy to 2025: Protecting Public Health at a Time of Rapid Change. European Medicines Agency. https://www.ema.europa.eu/en/documents/report/european-union-medicines-agencies-network-strategy-2025-protecting-public-health-time-rapid-change_en.pdf
Food and Drug Administration. (2011). Strategic Plan for Regulatory Science. U.S. Food and Drug Administration. https://www.fda.gov/science-research/advancing-regulatory-science/executive-summary-strategic-plan-regulatory-science
Ginter, P. M., Duncan, W. J., & Swayne, L. E. (2018). The strategic management of health care organizations. John Wiley & Sons.
Health Canada. (2023). 2023-24 Departmental Plan: Health Canada. Health Canada. https://www.canada.ca/en/health-canada/corporate/transparency/corporate-management-reporting/report-plans-priorities/2023-2024-departmental-plan.html
Hertelendy, A. J., Jaiswal, R., Donahue, J., & Reilly, M. J. (2024). Disaster risk management. In G. R. Ciottone (Ed.), Ciottone1s disaster medicine (3ª ed., pp. 178-190). Elsevier. https://doi.org/10.1016/B978-0-323-80932-0.00030-6
Hopkin, P. (2018). Fundamentals of risk management: understanding, evaluating and implementing effective risk management. Kogan Page Publishers.
Hubbard, D. W. (2020). The failure of risk management: Why it’s broken and how to fix it. John Wiley & Sons.
International Organization for Standardization. (2018). ISO 31000:2018 — Risk management — Guidelines. International Organization for Standardization.
Lauber, K., & Brooks, E. (2023). Why meta-regulation matters for public health: The case of the EU better regulation agenda. Globalization and Health, 19(1), 70. https://doi.org/10.1186/s12992-023-00971-4
Manickam, P., Mariappan, S. A., Murugesan, S. M., Hansda, S., Kaushik, A., Shinde, R., & Thipperudraswamy, S. P. (2022). Artificial intelligence (AI) and internet of medical things (IoMT) assisted biomedical systems for intelligent healthcare. Biosensors, 12(8), 562. https://doi.org/10.3390/bios12080562
Medicines and Healthcare Products Regulatory Agency. (2023). Corporate Plan 2023 to 2026. Medicines and Healthcare Products Regulatory Agency. https://www.gov.uk/government/publications/mhra-corporate-plan-2023-to-2026/medicines-and-healthcare-products-regulatory-agency-corporate-plan-2023-to-2026
Oliveira, C. V. D. S., & Pepe, V. L. E. (2024). Política de saúde e Autoridades Reguladoras: desafios da regulação de tecnologias nas Emergências em Saúde Pública. Ciência & Saúde Coletiva, 29(7), e03442024. https://doi.org/10.1590/1413-81232024297.03442024
Pepe, V. L. E., Albuquerque, M. V., & Oliveira, C. V. S. (2024). Emergências em saúde pública: o papel das agências reguladoras para a resiliência do sistema de saúde. Revista Panamericana de Salud Pública, 48, e130. https://doi.org/10.26633/RPSP.2024.130
Porter, M. E., & Heppelmann, J. E. (2014). How smart, connected products are transforming competition. Harvard business review, 92(11), 64-88.
Putrik, P., Jessup, R., Buchbinder, R., Glasziou, P., Karnon, J., & O’Connor, D. A. (2021). Prioritising models of healthcare service delivery for a more sustainable health system: A Delphi study of Australian health policy, clinical practice and management, academic and consumer stakeholders. Australian Health Review, 45(4), 425-432. https://doi.org/10.1071/AH20160
DG Health and Food Safety. (2020). Strategic Plan 2020-2024: Ensuring Health and Food Safety in the European Union. European Commission. https://commission.europa.eu/system/files/2020-10/sante_sp_2020_2024_en.pdf
Silva, S. N., Mello, N. F. D., Ribeiro, L. R., Silva, R. E. D., & Cota, G. (2024). Implementação de tecnologias em saúde no Brasil: análise de orientações federais para o sistema público de saúde. Ciência & Saúde Coletiva, 29, e00322023. https://doi.org/10.1590/1413-81232024291.00322023
Therapeutic Goods Administration. (2023). Strategic Plan 2023-2024: Enhancing Health Through Regulatory Excellence. Therapeutic Goods Administration. https://www.tga.gov.au/resources/publication/publications/health-products-regulation-group-regulatory-science-strategy-2020-2025
Veiga, J. E. D. (2020). Saúde e sustentabilidade. Estudos Avançados, 34(99), 303-310. https://doi.org/10.1590/s0103-4014.2020.3499.018
Vilarins, G. C. M., Shimizu, H. E., & Gutierrez, M. M. U. (2012). A regulação em saúde: aspectos conceituais e operacionais. Saúde em Debate, 36, 640-647. http://dx.doi.org/10.1590/S0103-11042012000400016.
World Health Organization. (2024). WHO Global Benchmarking Tool (GBT) for Evaluation of National Regulatory System of Medical Products: Manual for Benchmarking and Formulation of Institutional Development Plans. World Health Organization.
Yu, K. H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. Nature biomedical engineering, 2(10), 719-731. https://doi.org/10.1038/s41551-018-0305-z
How to Cite
License
Copyright (c) 2025 JOAO PAULO MOTA, Lucas Lima Moreno, Pedro Vilela, Gustavo Henrique Trindade da Silva

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Los contenidos de la revista se distribuyen bajo la licencia Creative Commons Reconocimiento-NoComercial 4.0 Internacional (CC BY-NC-4.0), que permite a los usuarios copiar, usar, difundir, transmitir y exponer públicamente los contenidos, siempre y cuando se cite la autoría (https://creativecommons.org/licenses/by-nc/4.0).